First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients

MedicalXpress | Jul 10, 2026

Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, underscoring the need for innovative research and new treatments that can improve both survival and quality of life for patients and their families.